Tags » Systemic Lupus Erythematosus

Researchers find protein that triggers lupus-associated immune system activation

Researchers have identified an inflammatory molecule that appears to play an essential role in the autoimmune disorder systemic lupus erythematosus, commonly known simply as lupus. In their report the team describes finding that a protein that regulates certain cells in the innate immune system – the body’s first line of defense against infection – activates a molecular pathway known to be associated with lupus and that the protein’s activity is required for the development of lupus symptoms in a mouse model of the disease. 414 more words


Erythema Multiforme

Erythema Multiforme

Usually I begin with a breakdown of definitions on the word origins to show how the name relates to the illness I am about to describe. 709 more words


“No Sleep Til Dawn.”- How to prepare yourself for a goodnights rest.

Judging by the title I’m sure many of you already know what this blog post is going to be about. It’s about the one thing that majority of us don’t get enough of, SLEEP. 304 more words

Autoimmune Disease

Lupus and Contraception

A little talked about topic has been ever on my mind since I first found out what was going wrong with my body. To be honest the omission to this topic as a whole in the larger chronic, lupus and autoimmune illness communities… 1,008 more words


Lupus Is Not Genetic Or Autoimmune - Reverse The Inflammation Naturally

Lupus is widely regarded in the conventional medical community as an inflammatory autoimmune disease that has its root cause in genetic factors. If you believe that your genes want you to have lupus then all you can do is suppress your immune system with man made synthetic chemicals. 305 more words


Greetings and Salutations !!!!

Hello everyone and welcome to my lovely blog, where I will give you all of the insight on how I stay happy and healthy in this wild world! 319 more words

Autoimmune Disease

Concerns on UCB/Immunomedics’ Phase III lupus trials

UCB and Immunomedics (NASDAQ: IMMU) expect top-line data from two Phase III trials (EMBODY 1 and EMBODY 2) of epratuzumab in 2015H1. Immunomedics’ fate hangs on the EMBODY trials, but the Phase IIb results that supported the EMBODY trials were not really all that good. 297 more words

Biotech Stocks